scispace - formally typeset
S

Scott P. Runyon

Researcher at Research Triangle Park

Publications -  69
Citations -  1039

Scott P. Runyon is an academic researcher from Research Triangle Park. The author has contributed to research in topics: Agonist & Opioid receptor. The author has an hindex of 20, co-authored 67 publications receiving 883 citations. Previous affiliations of Scott P. Runyon include RTI International & University of Minnesota.

Papers
More filters
Journal ArticleDOI

Functionalized 6-(Piperidin-1-yl)-8,9-Diphenyl Purines as Peripherally Restricted Inverse Agonists of the CB1 Receptor.

TL;DR: Piperidine is studied as a linker, which is functionalized with alkyl, heteroalkyl, aryl and heteroaryl groups using a urea connector, which resulted in orally bioavailable and peripherally selective compounds that are potent inverse agonists of hCB1 with exceptional selectivity for hCB2.
Journal ArticleDOI

17β-Nitro-5α-androstan-3α-ol and its 3β-methyl derivative: Neurosteroid analogs with potent anticonvulsant and anxiolytic activities

TL;DR: It is concluded that nitro can serve as a bioisostere for acetyl at the 17beta-position of 5alpha-androstan-3alpha-ol, such that the nitro analog fully retains the bioactivity of the endogenous neurosteroid at GABA(A) receptors.
Journal ArticleDOI

The amide linker in nonpeptide neurotensin receptor ligands plays a key role in calcium signaling at the Neurotensin receptor type 2

TL;DR: It is found that reversed amides display a shift from agonist to antagonist activity and the first competitive nonpeptide antagonists observed in the NTS2 FLIPR assay will be valuable tools for determining the role of calcium signaling in vitro to NTS2 mediated pain.
Journal ArticleDOI

A therapeutic combination of metyrapone and oxazepam increases brain levels of GABA-active neurosteroids and decreases cocaine self-administration in male rats

TL;DR: Data is presented demonstrating that this MET/OX combination enhances brain levels of the GABA-active steroid metabolites, tetrahydrodeoxycorticosterone (THDOC) and allopregnanolone, which have been shown to reduce cocaine-related behaviors and may contribute to the behavioral effects of MET/Ox combination therapy.